Abstract
The development of gene-inactivation systems is an active and important field for both functional genomics and gene therapy. Towards this end, ribozymes (i.e. RNA enzymes), that specifically recognize and subsequently catalyze the cleavage of other target RNA molecules, are attractive molecular tools. Ribozymes represent an interesting alternative to the RNA interference (RNAi) approach for gene inactivation, especially given the fact that RNAi seems to trigger an immunological response and has demonstrated off-target effects. However, the design and optimization of a ribozymebased gene-inactivation system is not a straightforward procedure. Several aspects need to be considered in the experimental design in order to provide a suitable suppression system. In this review we present the advances in this domain made available from work using the hepatitis delta virus (HDV) ribozyme as a cis-acting RNA motif in molecular biology, as well as a trans-acting molecular scissor for the development of a gene-inactivation system. This HDV ribozyme technology possesses several unique features that are all related to the fact that it is the only catalytic cleaving RNA motif that has been discovered in humans.
Keywords: HDV ribozyme, RNA interference, antisense, ribozyme, deoxyribozyme, RNase P, functional genomic, gene therapy
Current Gene Therapy
Title: Development of Ribozyme-Based Gene-Inactivations; The Example of the Hepatitis Delta Virus Ribozyme
Volume: 7 Issue: 3
Author(s): M. Asif-Ullah, Michel Levesque, Gilles Robichaud and Jean-Pierre Perreault
Affiliation:
Keywords: HDV ribozyme, RNA interference, antisense, ribozyme, deoxyribozyme, RNase P, functional genomic, gene therapy
Abstract: The development of gene-inactivation systems is an active and important field for both functional genomics and gene therapy. Towards this end, ribozymes (i.e. RNA enzymes), that specifically recognize and subsequently catalyze the cleavage of other target RNA molecules, are attractive molecular tools. Ribozymes represent an interesting alternative to the RNA interference (RNAi) approach for gene inactivation, especially given the fact that RNAi seems to trigger an immunological response and has demonstrated off-target effects. However, the design and optimization of a ribozymebased gene-inactivation system is not a straightforward procedure. Several aspects need to be considered in the experimental design in order to provide a suitable suppression system. In this review we present the advances in this domain made available from work using the hepatitis delta virus (HDV) ribozyme as a cis-acting RNA motif in molecular biology, as well as a trans-acting molecular scissor for the development of a gene-inactivation system. This HDV ribozyme technology possesses several unique features that are all related to the fact that it is the only catalytic cleaving RNA motif that has been discovered in humans.
Export Options
About this article
Cite this article as:
Asif-Ullah M., Levesque Michel, Robichaud Gilles and Perreault Jean-Pierre, Development of Ribozyme-Based Gene-Inactivations; The Example of the Hepatitis Delta Virus Ribozyme, Current Gene Therapy 2007; 7 (3) . https://dx.doi.org/10.2174/156652307780859008
DOI https://dx.doi.org/10.2174/156652307780859008 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Cyclodextrin-based Materials for Removing Micropollutants From Wastewater
Current Organic Chemistry Telomerase Therapeutics for Degenerative Diseases
Current Molecular Medicine The Antidiabetic Therapeutic Potential of Dietary Polyphenols
Current Pharmaceutical Biotechnology Bevacizumab in Non Small Cell Lung Cancer: Development, Current Status and Issues
Current Medicinal Chemistry Crosstalk between IGF-1R and other Tumor Promoting Pathways
Current Pharmaceutical Design Collateral Damage: Contribution of Peripheral Inflammation to Neurodegenerative Diseases
Current Topics in Medicinal Chemistry Pharmacophore Generation and 3D-QSAR of Novel 2-(quinazolin-4- ylamino)-[1,4] Benzoquinone Derivatives as VEGFR-2 Inhibitors
Letters in Drug Design & Discovery Aromatase Inhibitors: A New Paradigm in Breast Cancer Treatment
Current Medicinal Chemistry - Anti-Cancer Agents Polypharmacological Properties and Therapeutic Potential of β-Caryophyllene: A Dietary Phytocannabinoid of Pharmaceutical Promise
Current Pharmaceutical Design Peptide-Mediated Delivery of Therapeutic and Imaging Agents Into Mammalian Cells
Current Pharmaceutical Design Embryonic Stem Cell-Based Screen for Small Molecules: Cluster Analysis Reveals Four Response Patterns in Developing Neural Cells
Current Medicinal Chemistry Potential Approaches for Beta Cell Imaging with PET and SPECT
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Nonsteroidal Aromatase Inhibitors for the Treatment of Breast Cancer: An Update
Anti-Cancer Agents in Medicinal Chemistry Multifactorial Regulation of GPER Expression in Cancer Cells and Cardiomyocytes
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) UV Sunscreens of Microbial Origin: Mycosporines and Mycosporine- like Aminoacids
Recent Patents on Biotechnology Increased Paternal Age and Child Health and Development
Current Pediatric Reviews Possible Consequences of Blocking Transient Receptor Potential Vanilloid 1
Current Pharmaceutical Biotechnology Proteomic Classification of Breast Cancer
Current Drug Targets Immune Checkpoint Inhibitors for Non-small-cell Lung Cancer: Does that Represent a ‘New Frontier’?
Anti-Cancer Agents in Medicinal Chemistry Meet Our Editorial Board Member:
Medicinal Chemistry